A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials
Amer M. Zeidan; Maximilian Stahl; Mikkael A. Sekeres; David P. Steensma; Rami S. Komrokji; Steven D. Gore
Author Information: Department of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.